shutterstock_1569359980_sundry_photography

Sundry Photography / Shutterstock.com

31 March 2020Big PharmaRory O'Neill

Gilead expands special access to potential COVID-19 drug

Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead backs away from antiviral monopoly after criticism

26 March 2020 Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More on this story

Gilead backs away from antiviral monopoly after criticism

26 March 2020 Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More on this story

Gilead backs away from antiviral monopoly after criticism

26 March 2020 Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers